Jennifer Lin Hsiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer Lin Hsiao has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Yan Shi
Department of Dermatology University of Washington Seattle Washington USA
64 shared publications Vivian Y. Shi
Department of Dermatology, University of Washington, Seattle, WA, USA
27 shared publications- Kyla N. Price
College of Medicine, University of Illinois, Chicago, IL, United States
15 shared publications Justine R. Seivright
David Geffen School of Medicine, University of California, Los Angeles, California, USA
13 shared publications- Swetha Atluri
University of Arizona College of Medicine Tucson AZ USA
11 shared publications Alyssa M. Thompson
College of Medicine, University of Arizona, Tucson, Arizona, USA
10 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 3861-3904
The Impact of Chronic Spontaneous Urticaria on Sleep—A Systematic Review
Sleep disturbance is increasingly recognized as an important dimension of morbidity in chronic spontaneous urticaria (CSU), yet existing evidence remains fragmented across clinical, psychosocial, and physiologic domains. We conducted a systematic review of studies identified through PubMed, Embase, Web of Science, CENTRAL, and ClinicalTrials.gov to evaluate the prevalence, associated factors, and biologic correlates of sleep dysfunction in CSU, including subjective and objective sleep measures, sleep-disordered breathing (SDB), and potential biomarkers. Across cohorts, sleep disturbance was consistently reported and was more common in patients with CSU than in controls. Patients with CSU generally demonstrated worse global sleep quality, shorter sleep duration, longer sleep latency, and greater insomnia severity. Poor sleep was commonly associated with higher disease activity (UAS7), lower disease control (UCT), and worse quality of life (QoL) outcomes. Sleep impairment frequently co-occurred with anxiety, depression, fatigue, headache, and additional systemic symptom burden. Emerging biomarker data suggested possible circadian-immune dysregulation, including altered melatonin and orexin signaling in patients with CSU. SDB, including increased obstructive sleep apnea (OSA) risk and higher apnea-hypopnea indices, was reported in select cohorts and was generally more frequent among patients with greater urticaria activity. Limitations include heterogeneity in study design and the predominance of cross-sectional data, with limited objective sleep testing and biomarker assessment across cohorts. Despite these considerations, the available evidence indicates that sleep dysfunction in CSU is common, multifactorial, and clinically meaningful, supporting routine sleep assessment to improve comprehensive disease management.
- 29 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 3861-3904
Open AccessThe Impact of Chronic Spontaneous Urticaria on Sleep—A Systematic Review
Sleep disturbance is increasingly recognized as an important dimension of morbidity in chronic spontaneous urticaria (CSU), yet existing evidence remains fragmented across clinical, psychosocial, and physiologic domains. We conducted a systematic review of studies identified through PubMed, Embase, Web of Science, CENTRAL, and ClinicalTrials.gov to evaluate the prevalence, associated factors, and biologic correlates of sleep dysfunction in CSU, including subjective and objective sleep measures, sleep-disordered breathing (SDB), and potential biomarkers. Across cohorts, sleep disturbance was consistently reported and was more common in patients with CSU than in controls. Patients with CSU generally demonstrated worse global sleep quality, shorter sleep duration, longer sleep latency, and greater insomnia severity. Poor sleep was commonly associated with higher disease activity (UAS7), lower disease control (UCT), and worse quality of life (QoL) outcomes. Sleep impairment frequently co-occurred with anxiety, depression, fatigue, headache, and additional systemic symptom burden. Emerging biomarker data suggested possible circadian-immune dysregulation, including altered melatonin and orexin signaling in patients with CSU. SDB, including increased obstructive sleep apnea (OSA) risk and higher apnea-hypopnea indices, was reported in select cohorts and was generally more frequent among patients with greater urticaria activity. Limitations include heterogeneity in study design and the predominance of cross-sectional data, with limited objective sleep testing and biomarker assessment across cohorts. Despite these considerations, the available evidence indicates that sleep dysfunction in CSU is common, multifactorial, and clinically meaningful, supporting routine sleep assessment to improve comprehensive disease management.
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2634-2637
Application Site Adverse Events of Topical Nonsteroidal Immunomodulators: A Post‐Marketing Analysis of the FDA Adverse Event Reporting System
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (12) , 2634-2637
Application Site Adverse Events of Topical Nonsteroidal Immunomodulators: A Post‐Marketing Analysis of the FDA Adverse Event Reporting System
- Open Access
- 3 April 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 72, 131-134
A case of eosinophilic dermatosis of hematologic malignancy treated with omalizumab
- 3 April 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 72, 131-134
Open AccessA case of eosinophilic dermatosis of hematologic malignancy treated with omalizumab
- 14 January 2026
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 12 (4) , 1-4
An Update to Ethnoracial Gaps in Global Hidradenitis Suppurativa Clinical Trials
Introduction: Hidradenitis suppurativa (HS) disproportionately affects ethnoracial minority populations, particularly Black and Hispanic individuals. However, representation in randomized controlled trials remains limited. We aim to assess ethnoracial representation and reporting in HS trials conducted over the past 5 years. Methods: Phase 2 and 3 trials completed between 2019 and 2025 were identified via ClinicalTrials.gov. Trials with results and publications were included. Participant ethnoracial data were extracted, and PubMed supplemented missing data. Results: Among the 17 trials included in analysis, 76.2% (n = 2,652) of participants were white, 13.0% (n = 451) Black/African American, 6.0% (n = 210) Asian, 1.9% (n = 66) more than one race, 1.0% (n = 36) American Indian or Alaska Native, and 0.1% (n = 4) Native Hawaiian or other Pacific Islander. A total of 5.2% (n = 181) were Hispanic/Latino, although only 58.8% (n = 10) of trials reported these data. Of remaining participants, 1.8% (n = 63) were recorded as “unknown/not reported.” Geographically, all 17 (100%) trials had site locations in North America, 70.6% (n = 12) of trials had a site location in Europe, 41.2% (n = 7) in Australia, 41.2% (n = 7) in Asia, 11.8% (n = 2) in South America, and 5.9% (n = 1) in Africa. Conclusions: We found improved reporting of race and ethnicity in global HS clinical trials, yet Black and Hispanic/Latino patients remain underrepresented. Additionally, a lack of trials conducted in Africa, Asia, and South America could explain the lack of a global representation in participant demographics. Future trials should conduct stratified analyses to evaluate efficacy across global populations.
- 14 January 2026
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 12 (4) , 1-4
An Update to Ethnoracial Gaps in Global Hidradenitis Suppurativa Clinical Trials
Introduction: Hidradenitis suppurativa (HS) disproportionately affects ethnoracial minority populations, particularly Black and Hispanic individuals. However, representation in randomized controlled trials remains limited. We aim to assess ethnoracial representation and reporting in HS trials conducted over the past 5 years. Methods: Phase 2 and 3 trials completed between 2019 and 2025 were identified via ClinicalTrials.gov. Trials with results and publications were included. Participant ethnoracial data were extracted, and PubMed supplemented missing data. Results: Among the 17 trials included in analysis, 76.2% (n = 2,652) of participants were white, 13.0% (n = 451) Black/African American, 6.0% (n = 210) Asian, 1.9% (n = 66) more than one race, 1.0% (n = 36) American Indian or Alaska Native, and 0.1% (n = 4) Native Hawaiian or other Pacific Islander. A total of 5.2% (n = 181) were Hispanic/Latino, although only 58.8% (n = 10) of trials reported these data. Of remaining participants, 1.8% (n = 63) were recorded as “unknown/not reported.” Geographically, all 17 (100%) trials had site locations in North America, 70.6% (n = 12) of trials had a site location in Europe, 41.2% (n = 7) in Australia, 41.2% (n = 7) in Asia, 11.8% (n = 2) in South America, and 5.9% (n = 1) in Africa. Conclusions: We found improved reporting of race and ethnicity in global HS clinical trials, yet Black and Hispanic/Latino patients remain underrepresented. Additionally, a lack of trials conducted in Africa, Asia, and South America could explain the lack of a global representation in participant demographics. Future trials should conduct stratified analyses to evaluate efficacy across global populations.
- Open Access
- 13 November 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 31
Hidradenitis Suppurativa Flare Management: a Review of Medical and Procedural Strategies
Purpose of Review: While flares are a well-recognized feature of hidradenitis suppurativa (HS), defining flares and selecting an appropriate management strategy can be challenging. This narrative review discusses approaches to HS flare identification and management, highlighting both preventive and therapeutic strategies. Recent Findings: For decades, topical and systemic antibiotics have been a mainstay of HS flare treatment due to their anti-inflammatory properties and quick onset. According to a 2024 survey of HS experts, trimethoprim-sulfamethoxazole and amoxicillin-clavulanate were the second and third most prescribed antibiotic monotherapy following tetracyclines, respectively. Preliminary evidence suggests that pairing amoxicillin-clavulanate with a prednisone taper may have potential for gaining rapid control of HS flares. Among topical treatments, clascoterone and ruxolitinib emerge as promising non-antimicrobial options for mild to moderate HS. Procedural strategies for flare management include intralesional steroids for acutely inflamed nodules or tunnels and punch incision and drainage for relief of painful abscesses. A survey study of 900 individuals with self-reported HS found that complementary and alternative medicine (CAM) interventions are perceived to be one of the most helpful tools for flare management. Summary: Flares have significant implications for the quality of life in patients with HS. In order to synergize anchor therapy of baseline disease with prompt control of flare activity, a multimodal approach of medical, procedural, and CAM interventions combined with trigger avoidance and patient education is critical.
- 13 November 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 31
Open AccessHidradenitis Suppurativa Flare Management: a Review of Medical and Procedural Strategies
Purpose of Review: While flares are a well-recognized feature of hidradenitis suppurativa (HS), defining flares and selecting an appropriate management strategy can be challenging. This narrative review discusses approaches to HS flare identification and management, highlighting both preventive and therapeutic strategies. Recent Findings: For decades, topical and systemic antibiotics have been a mainstay of HS flare treatment due to their anti-inflammatory properties and quick onset. According to a 2024 survey of HS experts, trimethoprim-sulfamethoxazole and amoxicillin-clavulanate were the second and third most prescribed antibiotic monotherapy following tetracyclines, respectively. Preliminary evidence suggests that pairing amoxicillin-clavulanate with a prednisone taper may have potential for gaining rapid control of HS flares. Among topical treatments, clascoterone and ruxolitinib emerge as promising non-antimicrobial options for mild to moderate HS. Procedural strategies for flare management include intralesional steroids for acutely inflamed nodules or tunnels and punch incision and drainage for relief of painful abscesses. A survey study of 900 individuals with self-reported HS found that complementary and alternative medicine (CAM) interventions are perceived to be one of the most helpful tools for flare management. Summary: Flares have significant implications for the quality of life in patients with HS. In order to synergize anchor therapy of baseline disease with prompt control of flare activity, a multimodal approach of medical, procedural, and CAM interventions combined with trigger avoidance and patient education is critical.
- Open Access
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 155-157
Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 155-157
Open AccessDual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report
- 7 July 2025
- Published by S. Karger AG in Dermatology
- Vol. 241 (4) , 410-414
Ethnoracial and Geographic Disparities in Global Atopic Dermatitis Clinical Trials: An Update
Introduction: Atopic dermatitis (AD) disproportionally impacts skin of color (SOC) patients, particularly black/African American children. The number of global AD clinical trials is growing exponentially as the AD medication pipeline expands. Thus, we aimed to provide an analysis of racial, ethnic, and geographical disparities in global AD trials. Methods: Race, ethnicity, and location data were extracted from phase 2 and 3 randomized, double-blind, placebo-controlled trials investigating AD therapies from July 2019 to December 2023 on ClinicalTrials.gov. To provide an update, data were compared to similar published data from Br J Dermatol. 2020;183(2):378–380 from January 2009 to July 2019. Results: Twenty-four completed, randomized controlled trials (RCTs) met the search criteria. North America hosted the highest percentage of RCTs. The majority of participants were white, followed by Asian, and black/African American. Conclusion: Despite growing awareness of how AD affects SOC patients, the majority of participants in AD clinical trials are still white. Further efforts to increase reporting and enrollment of diverse participants are critical to further improving clinical trial participant diversity.
- 7 July 2025
- Published by S. Karger AG in Dermatology
- Vol. 241 (4) , 410-414
Ethnoracial and Geographic Disparities in Global Atopic Dermatitis Clinical Trials: An Update
Introduction: Atopic dermatitis (AD) disproportionally impacts skin of color (SOC) patients, particularly black/African American children. The number of global AD clinical trials is growing exponentially as the AD medication pipeline expands. Thus, we aimed to provide an analysis of racial, ethnic, and geographical disparities in global AD trials. Methods: Race, ethnicity, and location data were extracted from phase 2 and 3 randomized, double-blind, placebo-controlled trials investigating AD therapies from July 2019 to December 2023 on ClinicalTrials.gov. To provide an update, data were compared to similar published data from Br J Dermatol. 2020;183(2):378–380 from January 2009 to July 2019. Results: Twenty-four completed, randomized controlled trials (RCTs) met the search criteria. North America hosted the highest percentage of RCTs. The majority of participants were white, followed by Asian, and black/African American. Conclusion: Despite growing awareness of how AD affects SOC patients, the majority of participants in AD clinical trials are still white. Further efforts to increase reporting and enrollment of diverse participants are critical to further improving clinical trial participant diversity.
- Open Access
- 5 July 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 63, 81-83
New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report
- 5 July 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 63, 81-83
Open AccessNew onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report
- 27 June 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (3) , 575-577
Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study of Demographics, Provider Landscape, and Comorbidities
- 27 June 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (3) , 575-577
Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study of Demographics, Provider Landscape, and Comorbidities